These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 22102444)

  • 1. Chronic cardiac allograft rejection: critical role of ED-A(+) fibronectin and implications for targeted therapy strategies.
    Franz M; Neri D; Berndt A
    J Pathol; 2012 Mar; 226(4):557-61. PubMed ID: 22102444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A+ fibronectin, alpha-smooth muscle actin and B+ tenascin-C in chronic cardiac allograft rejection.
    Franz M; Grün K; Richter P; Brehm BR; Fritzenwanger M; Hekmat K; Neri D; Gummert J; Figulla HR; Kosmehl H; Berndt A; Renner A
    Histochem Cell Biol; 2010 Nov; 134(5):503-17. PubMed ID: 20931338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo expression of fetal ED-A(+) fibronectin and B (+) tenascin-C splicing variants in human cardiac allografts: potential impact for targeted therapy of rejection.
    Franz M; Matusiak-Brückner M; Richter P; Grün K; Ziffels B; Neri D; Maschek H; Schulz U; Pfeil A; Jung C; Figulla HR; Gummert J; Berndt A; Renner A
    J Mol Histol; 2014 Oct; 45(5):519-32. PubMed ID: 24792713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted delivery of interleukin-10 to chronic cardiac allograft rejection using a human antibody specific to the extra domain A of fibronectin.
    Franz M; Doll F; Grün K; Richter P; Köse N; Ziffels B; Schubert H; Figulla HR; Jung C; Gummert J; Renner A; Neri D; Berndt A
    Int J Cardiol; 2015 Sep; 195():311-22. PubMed ID: 26056964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis.
    Booth AJ; Wood SC; Cornett AM; Dreffs AA; Lu G; Muro AF; White ES; Bishop DK
    J Pathol; 2012 Mar; 226(4):609-18. PubMed ID: 21960174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of extra domain A containing fibronectin in chronic cardiac allograft rejection.
    Franz M; Berndt A; Grün K; Richter P; Kosmehl H; Neri D; Gummert J; Figulla HR; Brehm BR; Renner A
    J Heart Lung Transplant; 2011 Jan; 30(1):86-94. PubMed ID: 20952210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allograft inflammatory factor-1 expression correlates with cardiac rejection and development of cardiac allograft vasculopathy.
    Autieri MV; Kelemen S; Thomas BA; Feller ED; Goldman BI; Eisen HJ
    Circulation; 2002 Oct; 106(17):2218-23. PubMed ID: 12390951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective imaging of chronic cardiac rejection using a human antibody specific to the alternatively spliced EDA domain of fibronectin.
    Franz M; Hilger I; Grün K; Kossatz S; Richter P; Petersen I; Jung C; Gummert J; Figulla HR; Kosmehl H; Neri D; Berndt A; Renner A
    J Heart Lung Transplant; 2013 Jun; 32(6):641-50. PubMed ID: 23701854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular HMGB1 Contributes to the Chronic Cardiac Allograft Vasculopathy/Fibrosis by Modulating TGF-β1 Signaling.
    Zou H; Ming B; Li J; Xiao Y; Lai L; Gao M; Xu Y; Tan Z; Gong F; Zheng F
    Front Immunol; 2021; 12():641973. PubMed ID: 33777037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiomyocyte-targeted HIF-1alpha gene therapy inhibits cardiomyocyte apoptosis and cardiac allograft vasculopathy in the rat.
    Keränen MA; Nykänen AI; Krebs R; Pajusola K; Tuuminen R; Alitalo K; Lemström KB
    J Heart Lung Transplant; 2010 Sep; 29(9):1058-66. PubMed ID: 20580263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of acute murine cardiac allograft rejection: anti-CD4 or anti-vascular cell adhesion molecule one monoclonal antibodies block acute rejection but permit persistent graft-reactive alloimmunity and chronic tissue remodelling.
    Orosz CG; Huang EH; Bergese SD; Sedmak DD; Birmingham DJ; Ohye RG; VanBuskirk AM
    J Heart Lung Transplant; 1997 Sep; 16(9):889-904. PubMed ID: 9322138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine C4d immunohistochemistry in cardiac allografts: Long-term outcomes.
    Husain AN; Mirza KM; Fedson SE
    J Heart Lung Transplant; 2017 Dec; 36(12):1329-1335. PubMed ID: 28988608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine-mediated fibronectin production and transendothelial migration of lymphocytes in the mechanism of cardiac allograft vascular disease: efficacy of novel therapeutic approaches.
    Rabinovitch M; Molossi S; Clausell N
    J Heart Lung Transplant; 1995; 14(6 Pt 2):S116-23. PubMed ID: 8719473
    [No Abstract]   [Full Text] [Related]  

  • 14. The experimental study of cardiac allograft vasculopathy and myocardial fibrosis in rats.
    Song G; Zhang J; Jiang D; Wang X; Xu J
    Transplant Proc; 2008 Oct; 40(8):2712-5. PubMed ID: 18929843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer cells play a critical role in cardiac allograft vasculopathy in an interleukin-6--dependent manner.
    Zhang ZX; Huang X; Jiang J; Lian D; Min WP; Liu W; Haig A; Jevnikar AM
    Transplantation; 2014 Nov; 98(10):1029-39. PubMed ID: 25286056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone prevents acute and chronic cardiac allograft rejection.
    Kosuge H; Haraguchi G; Koga N; Maejima Y; Suzuki J; Isobe M
    Circulation; 2006 Jun; 113(22):2613-22. PubMed ID: 16735678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune function surveillance: association with rejection, infection and cardiac allograft vasculopathy.
    Heikal NM; Bader FM; Martins TB; Pavlov IY; Wilson AR; Barakat M; Stehlik J; Kfoury AG; Gilbert EM; Delgado JC; Hill HR
    Transplant Proc; 2013; 45(1):376-82. PubMed ID: 23267802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Connective tissue growth factor (CTGF/CCN2): a protagonist in cardiac allograft vasculopathy development?
    Pantou MP; Manginas A; Alivizatos PA; Degiannis D
    J Heart Lung Transplant; 2012 Aug; 31(8):881-7. PubMed ID: 22503846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late onset antibody-mediated rejection and endothelial localization of vascular endothelial growth factor are associated with development of cardiac allograft vasculopathy.
    Bayliss J; Bailey M; Leet A; Stein AN; Thomson NM; McLean CA
    Transplantation; 2008 Oct; 86(7):991-7. PubMed ID: 18852667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased connective tissue growth factor expression in a rat model of chronic heart allograft rejection.
    Yuan YC; Xia ZK; Mu JJ; Zhang QC; Yin BL
    J Formos Med Assoc; 2009 Mar; 108(3):240-6. PubMed ID: 19293040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.